<DOC>
	<DOCNO>NCT02236065</DOCNO>
	<brief_summary>This open label trial conduct investigate efficacy safety combination therapy allogeneic umbilical cord blood ( UCB ) granulocyte-colony stimulate factor ( G-CSF ) patient brain injury neurodegenerative disorder .</brief_summary>
	<brief_title>Combination Therapy Cord Blood G-CSF Patients With Brain Injury Neurodegenerative Disorders</brief_title>
	<detailed_description>Current treatment brain injury neurodegenerative disorder palliative rather curative . Preclinical clinical study suggest UCB G-CSF use restorative approach disorder .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>include one 4 disorder Brain injury : onset duration 12 month , Age : 19 year Cerebral palsy : spastic , dyskinetic ataxic , Age : 19 year Parkinson 's disease : modify Hoehn Yahr stage 2.5 , 3 , 4 , Age : 30 75 year ALS : definite possible ALS , progression past 6 month , Age : 19 65 Uncontrolled pulmonary , renal dysfunction enrollment Uncontrolled seizure Malignant cancer Possibility hypersensitivity drug use study Contraindication study intervention assessment Pregnant breast feed woman Noncompliance study visit specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Umbilical cord blood</keyword>
	<keyword>Granulocyte-colony stimulating factor</keyword>
	<keyword>Brain injury</keyword>
	<keyword>Neurodegenerative disorder</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>